Schreiner MediPharm launches Cap-Lock label for prefilled syringes

Schreiner MediPharm has launched Cap-Lock, a novel functional label that combines the Schott Topac infuse COC syringe and an innovative specialty cap that can completely replace previous blister packaging.

Due to a new cap design having the same diameter as the syringe barrel, the Cap-Lock label can be reliably applied to the syringe. The functional label wraps around the syringe barrel and cap like a second skin. It offers an irreversible first-opening indication that is automatically activated when the cap is opened.

This functionality ensures the integrity of the prefilled syringe from production to final use. That avoids tampering and misuse; users can instantly recognize if the syringe and label have been opened previously.

Aside from the first opening indication, the Cap-Lock label performs additional protective functions of the conventional blister and transfers them to the primary container. A gas barrier, as well as multi-level UV and light protection, can be integrated into the label design.

The extended label space enables flexibility in terms of customized branding, product information, or drug color codes.

An RFID chip for automated tracking on the unit level and for digital-first opening indication can be integrated into the Cap-Lock label as well.

Due to the combination of the COC syringe with a specialty cap and functional label with a sealing function, the filled syringes can be packaged in a volume-optimized top-load cardboard box consisting of 100 percent mono-material from Körber Pharma. That ensures optimized packaging and distribution processes in pharmaceutical production and requires clearly less space for transportation and storage.

The new packaging offers considerable cost savings for pharmaceutical manufacturers but also significantly contributes to sustainability. Due to the non-use of blisters in the case of the 5 ml Schott Toppac infuse, 1,260 syringes more per pallet can be shipped, resulting in 16 containers being saved for ten million syringes.

Due to the elimination of the blister packaging, plastic materials and plastic waste are reduced by 80 percent. For instance, during one-time transportation of ten million 5-ml syringes from Hamburg to New York, CO2 reductions of up to 87,400 kilograms can be achieved.

Together with partnering companies SCHOTT Pharma and Körber Pharma, Schreiner MediPharm is going to show this new technology at this year’s Pharmapack in Paris from January 22 to 23.